Skip to main content

Drug Safety

      RT @Yuz6Yusof: Do we need to monitor #ECG in patients on #HCQ and #polypharmacy? Dr Antivalle reported ⬆️QTc interva
      3 years 10 months ago
      Do we need to monitor #ECG in patients on #HCQ and #polypharmacy? Dr Antivalle reported ⬆️QTc interval in HCQ vs controls. Only 3/132 was above ULN in HCQ group though. Importantly,⬆️QTc was noted more in HCQ + co-meds (e.g. PPI) #EULAR2021 #POS0090 @RheumNow https://t.co/1Ui4MghqIk
      RT @doctorRBC: ⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD
      ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD
      â
      3 years 10 months ago
      ⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD ⭐️No overall increase in all CA: RTX, TOCI ⭐️Abatacept 1.21HR for all cancer, mainly NMSC ⭐️needs more data on JAKs, IL-17, IL-23 Abs#6916 #EULAR2021 @RheumNow
      RT @MeralElRamahiMD: Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study?

      ⭐️187 bDMARD-naive, active AS
      3 years 10 months ago
      Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study? ⭐️187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID ⭐️82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64w 🚫 new safety signal & ZERO VTE, MACE, TB, or deaths w/ UPA. OP0144 #EULAR2021 @RheumNow https://t.co/mFbgQjsD6f
      RT @uptoTate: In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & r
      3 years 10 months ago
      In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u
      ×